TLDR
- ARK Invest bought 162,327 shares of CRISPR Therapeutics worth $10.06 million on November 4, 2025, split between ARKK and ARKG funds.
- The firm purchased 291,001 shares of Beam Therapeutics valued at $7.06 million, showing confidence in gene-editing companies.
- ARK sold 27,423 shares of Teradyne worth $5.02 million through ARKK, continuing recent semiconductor testing stock reductions.
- The investment firm trimmed its Roku position by 15,362 shares valued at $1.67 million through ARKK.
- ARK sold 20,485 shares of SoFi Technologies for $627,455 through ARKF while adding $1.20 million in Bullish shares across multiple ETFs.
Cathie Wood’s ARK Invest made major changes to its portfolio on November 4, 2025, buying heavily into biotech companies while reducing positions in technology and fintech stocks. The daily trading report revealed a clear shift in focus toward gene-editing firms.
ARK purchased 162,327 shares of CRISPR Therapeutics for about $10.06 million. The buy was split between the ARK Innovation ETF and the ARK Genomic Revolution ETF.
The investment firm also acquired 291,001 shares of Beam Therapeutics valued at $7.06 million. This purchase went through the same two funds, showing ARK’s commitment to the gene-editing sector.
Both CRISPR and Beam work in the gene-editing field. These buys demonstrate ARK’s belief in genomic medicine’s future growth potential.
ARK added 23,963 shares of Bullish worth $1.20 million across several ETFs. This move increased the firm’s holdings in digital assets.
Tech Stock Sales
On the selling side, ARK reduced its Teradyne position by 27,423 shares worth $5.02 million through ARKK. This continues a pattern of profit-taking in semiconductor testing stocks from the previous week.
The firm sold 15,362 shares of Roku valued at $1.67 million through the ARKK ETF. This marks another round of reductions in the streaming platform company.
Fintech Trimming
ARK sold 20,485 shares of SoFi Technologies for about $627,455 through the ARK Fintech Innovation ETF. This represents a small reduction in the firm’s fintech holdings.
The total biotech purchases of approximately $17.12 million far exceeded the sales in other sectors. The gene-editing investments accounted for the majority of ARK’s trading activity for the day.
The ARKK and ARKG funds handled most of the biotech purchases. These funds focus on innovation and genomic revolution themes respectively.
ARK’s trading activity on November 4 showed a clear preference for life sciences over technology. The firm moved capital from established tech stocks into emerging biotech companies.
The Teradyne sale extended recent reductions in semiconductor-related holdings. ARK has been adjusting its exposure to tech hardware stocks over recent weeks.
The Roku trimming continues a pattern of reducing streaming platform exposure. ARK has been gradually decreasing its stake in the company through multiple sales.
The CRISPR and Beam purchases represent ARK’s largest moves of the day. These two transactions dominated the firm’s trading volume and dollar value for November 4, 2025.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
